StockMacro
Menu

Immunovant

$31.77 -6.1% in 6 monthsMarket cap $6.6B

IMVT on XNAS, Health Care, Immunovant, Inc., job postings

Measures activity, not value. Not investment advice.

Net loss of $509M over twelve months while the stock rose 39% in a year.

  • BadShort interest at 9.0% of shares, 15.3 days to cover

Written by AI from the data on this page, 22 Nov 2026. Not investment advice.

Profile and fundamentals

From its SEC filings, 12 months to 30 Sep 2026

Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The Company operates in a single operating segment and has one reportable segment, which includes all activities related to the discovery, development and manufacturing of its product candidates.

Industry
Biological products, (no diagnostic substances) (Health Care)
Employees
315
Website
immunovant.com
Listed
Nasdaq, US
Last results
9 Nov 2026
Next results
expected around 5 Feb 2027 (an estimate: a year ago it reported on 6 Feb 2026)
Revenue and net income per quarter. Quarter to 30 Sep 2026: net loss $97.2M.
Quarter to 31 Dec 2021: revenue –, net income -$41.4MQuarter to 31 Mar 2022: revenue –, net income -$47.2MQuarter to 30 Jun 2022: revenue –, net income -$40.4MQuarter to 30 Sep 2022: revenue –, net income -$47.9MQuarter to 31 Dec 2022: revenue –, net income -$63.2MQuarter to 31 Mar 2023: revenue –, net income -$59.4MQuarter to 30 Jun 2023: revenue –, net income -$73.9MQuarter to 30 Sep 2023: revenue –, net income -$58.7MQuarter to 31 Dec 2023: revenue –, net income -$51.4MQuarter to 31 Mar 2024: revenue –, net income -$75.3MQuarter to 30 Jun 2024: revenue –, net income -$87.2MQuarter to 30 Sep 2024: revenue –, net income -$109.1MQuarter to 31 Dec 2024: revenue –, net income -$111.1MQuarter to 31 Mar 2025: revenue –, net income -$106.4MQuarter to 30 Jun 2025: revenue –, net income -$120.6MQuarter to 30 Sep 2025: revenue –, net income -$126.5MQuarter to 31 Dec 2025: revenue –, net income -$110.6MQuarter to 31 Mar 2026: revenue –, net income -$147.9MQuarter to 30 Jun 2026: revenue –, net income -$153.2MQuarter to 30 Sep 2026: revenue –, net income -$97.2M
31 Dec 2021RevenueNet incomeNet losstallest bar $153.2M30 Sep 2026
See the numbers
Quarter toRevenueNet income
30 Sep 2026–-$97.2M
30 Jun 2026–-$153.2M
31 Mar 2026–-$147.9M
31 Dec 2025–-$110.6M
30 Sep 2025–-$126.5M
30 Jun 2025–-$120.6M
31 Mar 2025–-$106.4M
31 Dec 2024–-$111.1M
30 Sep 2024–-$109.1M
30 Jun 2024–-$87.2M
31 Mar 2024–-$75.3M
31 Dec 2023–-$51.4M
30 Sep 2023–-$58.7M
30 Jun 2023–-$73.9M
31 Mar 2023–-$59.4M
31 Dec 2022–-$63.2M
30 Sep 2022–-$47.9M
30 Jun 2022–-$40.4M
31 Mar 2022–-$47.2M
31 Dec 2021–-$41.4M
Fundamentals, 12 months to 30 Sep 2026
MeasureLatestYear beforePeer median
RevenueSales over the last 12 months reported. – –
Revenue growthRevenue of the last 12 months compared with the 12 months before. – +8.2%
Net incomeProfit after all costs and taxes over the last 12 months reported. Negative is a loss. -$509.0M -$464.7M
EPS (diluted)Earnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split). -$2.56 -$2.83
Gross marginWhat is left of each dollar of sales after the direct cost of making the product or service. – – 70.4%
Operating marginOperating income as a share of sales: profit from the business before interest and taxes. – – -98.6%
Net marginNet income as a share of sales: what the owners keep of each dollar sold. – – -47.8%
Return on equityNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money. -86.5% -58.2%
Free cash flowCash from operations minus capital spending over the last 12 months: cash the business produced. – -$431.3M
CashCash, cash equivalents and short-term investments on the latest balance sheet. $722.3M $521.9M
DebtShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted. $0 $0
Net debtDebt minus cash. Negative means the company holds more cash than it owes (net cash). -$722.3M (net cash) -$521.9M
Debt to equityDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative. 0.0 0.0
Book value per shareShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding. $3.17
P/EPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss. loss 21.6
P/SPrice to sales: market cap divided by revenue of the last 12 months. – 8.0
EV/SalesEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months. – 6.0
P/BPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative. 10.0 2.0

Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.

Peers nearest by market cap, its own industry first

CompanyMarket capP/EP/SRevenue growthNet margin
ImmunovantIMVT (this company) $6.6Bloss–––
ImmunityBioIBRX $6.4Bloss35.1+121%-608%
Kodiak SciencesKOD $6.4Bloss–––
Twist BioscienceTWST $7.0Bloss15.3+22%-28.3%
CG OncologyCGON $7.1Blossover 999+184%–
Scholar RockSRRK $5.9Blossover 999––

Insider Buy/Sell Shares the company's insiders (directors, officers and owners of 10% or more) bought minus what they sold on the open market in the last 90 days, from their Form 4 filings.

-$896K

bought $0, sold $896K

Institutional holders The number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.

+2.7%

229 13F filers vs 223

Institutional ownership Shares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.

53%

108.9M shares held by 13F filers (30 Sep 2026) of 206.9M outstanding (3 Nov 2026)

Short interest Shares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.

9.0%

18.6M shares sold short (30 Oct 2026) of 206.9M outstanding (3 Nov 2026)

Days to cover Short interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.

15.3

18.6M shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it

Short interest change How the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.

+1.5%

18.3M shares sold short in the report before, 18.6M on 30 Oct 2026

Short sale volume Share of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.

71%

71% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 60%

Open jobs Job postings open on the company's own careers site today, where we track it. Blank when we do not track this company's careers site yet.

12

Tracked since 20 Nov 2026

Open jobs change How the number of open job postings changed over the last 30 days: total hiring demand, any job, any country. Shown only once we have tracked the company for 30 days.

–

Tracking started 20 Nov 2026; the change shows after 30 days.

Employees Total staff the company reported in its latest annual report (10-K), with the change from the year before when both years are reported.

–

No headcount in its annual reports in our data.

Visa hiring (foreign workers) Applications to hire foreign specialists on H-1B and E-3 visas certified by the Labor Department in the last 12 months, compared with the 12 months before. This is NOT total hiring: most hires need no visa. Open jobs shows total hiring where we track it.

–

No data for this company

Revenue growth Sales in the latest reported quarter compared with the same quarter a year earlier.

–

No data for this company

Capital spending Money spent on buildings, machines and equipment in the latest quarter, compared with the same quarter a year earlier.

–

No data for this company

Federal contracts Money the US government committed to the company in contracts and grants over the last 12 months.

–

No data for this company

Lobbying What the company reported spending on federal lobbying over the last four quarters.

–

No data for this company

Layoff notices Workers named in state WARN layoff notices over the last 12 months (employers must file them 60 days before a large layoff).

–

No data for this company

News (7d) Articles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.

6

6 articles in the last 7 days; its usual week has 1 (the median of the 26 weeks before).

News vs usual Articles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.

6.0×

6 articles in the last 7 days; its usual week has 1.

Price $31.77 on 20 Nov 2026, +39% over 12 months (12-month range $22.02 to $44.96)

  • Sharp change
  • 8-K and other filings
Insider net buying (open market). Insiders bought a net $333.7M in the last 12 months (the 12 months before: $333.8M).
Capital spending per quarter. Capital spending $8K in the latest quarter, -96% on a year earlier.
Institutional holders (13F filers). 229 13F filers reported holding it in the latest 13F quarter, +29% on a year earlier.

Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: h-1b/e-3 applications certified, revenue per quarter, federal obligations, lobbying spend, workers in warn layoff notices.

See the numbers
Dated facts on the price chart (newest 100)
Became publicKindFact
21 Nov 20258-K and other filingsDirector or officer change
21 Nov 2025Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
29 Jul 2025Sharp changeShort interest spike: short interest spike, 20.6M vs usual 13.1M (2025-07-15); 2.0x the same period a year earlier
29 Jul 20258-K and other filingsDirector or officer change
29 Jul 2025Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
1 Jul 2025Sharp changeShort interest spike: short interest spike, 19.9M vs usual 12.9M (2025-06-13); 2.0x the same period a year earlier
17 Jun 2025Sharp changeShort interest spike: short interest spike, 21.7M vs usual 12.7M (2025-05-30); 2.4x the same period a year earlier
3 Jun 2025Sharp changeShort interest spike: short interest spike, 21.4M vs usual 12.7M (2025-05-15); 2.3x the same period a year earlier
13 May 2025Sharp changeShort interest spike: short interest spike, 20.7M vs usual 12.6M (2025-04-30); 2.3x the same period a year earlier
29 Apr 2025Sharp changeShort interest spike: short interest spike, 20.8M vs usual 12.5M (2025-04-15); 2.4x the same period a year earlier
21 Apr 20258-K and other filingsDirector or officer change
21 Apr 2025Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
15 Apr 2025Sharp changeShort interest spike: short interest spike, 19.7M vs usual 12.4M (2025-03-31); 2.2x the same period a year earlier
21 Jan 20258-K and other filingsPrivate placement of securities (Form D)
14 Nov 2023Sharp changeMany funds opening a new position: many funds opening a new position, 56 vs usual 22 (2023-09-30); 2.7x the same period a year earlier
17 Oct 2023Sharp changeShort interest spike: short interest spike, 7.3M vs usual 3.5M (2023-09-29); 2.6x the same period a year earlier
2 May 2023Sharp changeShort interest spike: short interest spike, 4.7M vs usual 2.6M (2023-04-14); 1.9x the same period a year earlier
18 Apr 2023Sharp changeShort interest spike: short interest spike, 4.9M vs usual 2.5M (2023-03-31); 2.1x the same period a year earlier
8 Oct 2022Sharp changeClustered insider buying: clustered insider buying (3 independent filers, 3 filing(s) in 30 days, value_usd total 2.7M)
Insider net buying (open market)
Month from 1 Jan 2022: -$1.7M published
Month from 1 Apr 2022: -$168K published
Month from 1 May 2022: -$7K published
Month from 1 Jul 2022: -$18K published
Month from 1 Sep 2022: $93K published
Month from 1 Oct 2022: $2.4M published
Month from 1 Jan 2023: -$2.1M published
Month from 1 Feb 2023: -$10K published
Month from 1 Apr 2023: -$179K published
Month from 1 Jul 2023: -$256K published
Month from 1 Aug 2023: -$5.5M published
Month from 1 Sep 2023: -$1.3M published
Month from 1 Oct 2023: $57.4M published
Month from 1 Nov 2023: -$985K published
Month from 1 Dec 2023: -$1.5M published
Month from 1 Jan 2024: -$860K published
Month from 1 Feb 2024: -$827K published
Month from 1 Apr 2024: -$2.9M published
Month from 1 May 2024: -$888K published
Month from 1 Jul 2024: -$1.2M published
Month from 1 Aug 2024: -$898K published
Month from 1 Oct 2024: -$1.1M published
Month from 1 Nov 2024: -$709K published
Month from 1 Dec 2024: -$376K published
Month from 1 Jan 2025: $336.2M published
Month from 1 Feb 2025: -$424K published
Month from 1 Mar 2025: -$157K published
Month from 1 Apr 2025: -$885K published
Month from 1 Jul 2025: -$140K published
Month from 1 Oct 2025: -$144K published
Month from 1 Nov 2025: -$298K published
Month from 1 Dec 2025: $348.8M published
Month from 1 Jan 2026: -$83K published
Month from 1 Feb 2026: -$90K published
Month from 1 Mar 2026: -$72K published
Month from 1 Apr 2026: -$1.8M published
Month from 1 May 2026: -$7.8M published
Month from 1 Jun 2026: -$3.5M published
Month from 1 Jul 2026: -$818K published
Month from 1 Aug 2026: -$200K published
Month from 1 Sep 2026: -$103K published
Month from 1 Oct 2026: -$619K published
Month from 1 Nov 2026: -$108K published
Capital spending per quarter
Quarter ended 31 Dec 2021: $74K, +155% on a year earlier; public on 5 Feb 2022
Quarter ended 31 Mar 2022: $118K, +24% on a year earlier; public on 9 Jun 2022
Quarter ended 30 Jun 2022: $42K, +133% on a year earlier; public on 6 Aug 2022
Quarter ended 30 Sep 2022: $31K, -30% on a year earlier; public on 5 Nov 2022
Quarter ended 31 Dec 2022: $98K, +32% on a year earlier; public on 4 Feb 2023
Quarter ended 31 Mar 2023: $26K, -78% on a year earlier; public on 23 May 2023
Quarter ended 30 Jun 2023: $45K, +7.1% on a year earlier; public on 11 Aug 2023
Quarter ended 30 Sep 2023: $34K, +9.7% on a year earlier; public on 10 Nov 2023
Quarter ended 31 Dec 2023: $131K, +34% on a year earlier; public on 13 Feb 2024
Quarter ended 31 Mar 2024: $150K, +477% on a year earlier; public on 30 May 2024
Quarter ended 30 Jun 2024: $182K, +304% on a year earlier; public on 7 Aug 2024
Quarter ended 30 Sep 2024: $196K, +476% on a year earlier; public on 8 Nov 2024
Quarter ended 31 Dec 2024: $180K, +37% on a year earlier; public on 7 Feb 2025
Quarter ended 31 Mar 2025: $201K, +34% on a year earlier; public on 30 May 2025
Quarter ended 30 Jun 2025: $0, -100% on a year earlier; public on 12 Aug 2025
Quarter ended 30 Sep 2025: $0, -100% on a year earlier; public on 11 Nov 2025
Quarter ended 31 Dec 2025: $0, -100% on a year earlier; public on 7 Feb 2026
Quarter ended 31 Mar 2026: $8K, -96% on a year earlier; public on 21 May 2026
Institutional holders (13F filers)
31 Dec 2021 report: 106; public on 14 Feb 2022
31 Mar 2022 report: 104; public on 16 May 2022
30 Jun 2022 report: 88; public on 15 Aug 2022
30 Sep 2022 report: 102; public on 14 Nov 2022
31 Dec 2022 report: 126; public on 14 Feb 2023
31 Mar 2023 report: 138; public on 15 May 2023
30 Jun 2023 report: 142; public on 14 Aug 2023
30 Sep 2023 report: 173; public on 14 Nov 2023
31 Dec 2023 report: 216; public on 14 Feb 2024
31 Mar 2024 report: 198; public on 15 May 2024
30 Jun 2024 report: 188; public on 14 Aug 2024
30 Sep 2024 report: 178; public on 14 Nov 2024
31 Dec 2024 report: 184; public on 14 Feb 2025
31 Mar 2025 report: 189; public on 15 May 2025
30 Jun 2025 report: 162; public on 14 Aug 2025
30 Sep 2025 report: 178; public on 14 Nov 2025
31 Dec 2025 report: 193; public on 17 Feb 2026
31 Mar 2026 report: 211; public on 15 May 2026
30 Jun 2026 report: 223; public on 14 Aug 2026
30 Sep 2026 report: 229; public on 16 Nov 2026

What is unusual now

  • Nothing unusual in the last 90 days: no change appeared. Its most unusual measure now is operating income, quarter at -$420K (30 Sep 2019), 355% below its normal quarter of -$92K.
  • Insider net buying (open market): Insiders bought a net $333.7M in the last 12 months (the 12 months before: $333.8M).
  • Capital spending per quarter: Capital spending $8K in the latest quarter, -96% on a year earlier.
  • Institutional holders (13F filers): 229 13F filers reported holding it in the latest 13F quarter, +29% on a year earlier.

Latest records

The names and amounts behind the totals, newest first

Last 90 days: 9 sales, $896K; no purchases. Open-market trades by officers, directors and 10% owners.

FiledInsiderTradeSharesPriceValueSource
12 Nov 2026Atul PandeDirectorSellplanned in advance (10b5-1); after exercising options3,000$36.00$108KForm 4
30 Oct 2026Tiago GiraoChief Financial OfficerSell6,606$28.50$188KForm 4
23 Oct 2026Jay S StoutChief Technology OfficerSell2,595$28.94$75KForm 4
9 Oct 2026Jay S StoutChief Technology OfficerSell3,809$32.06$122KForm 4
9 Oct 2026Christopher Van TuylChief Legal OfficerSell1,327$32.06$43KForm 4
9 Oct 2026Melanie GloriaChief Operating OfficerSell2,241$32.06$72KForm 4
5 Oct 2026Eric VenkerChief Executive OfficerSellafter exercising options3,506$34.11$120KForm 4
25 Sep 2026Christopher Van TuylChief Legal OfficerSell2,846$36.36$103KForm 4

229 institutions reported shares at the end of Q3 2026, 53% of the shares outstanding; 33 opened a position, 27 sold out. From 13F reports.

InstitutionShares% of companyValueChange vs Q2 2026
FMR LLC (Fidelity)15.7M7.59%$530.5M-482K-3.0%
Deep Track Capital, LP9.2M4.43%$309.5M-180K-1.9%
BlackRock, Inc.7.4M3.59%$250.8M+245K+3.4%
Farallon Capital Management, L.L.C.6.5M3.13%$218.6M+666K+11%
Morgan Stanley5.7M2.75%$192.0M+1.2M+25%
Two Seas Capital LP4.6M2.23%$155.8M+1.5M+47%
TCG Crossover Management, LLC4.5M2.15%$150.6MNo change
Vanguard Portfolio Management LLC4.3M2.06%$144.1M+354K+9.1%
State Street Corp4.2M2.03%$141.8M-421K-9.1%
Vanguard Capital Management LLC4.1M1.98%$138.1M+449K+12%

Company events

All 29 company events

Nothing in 12 months; the latest was filed 21 Nov 2025. Results releases and routine reports are left out.

FiledWhat happenedSource
21 Nov 2025Director or officer change8-K
29 Jul 2025Director or officer change8-K
21 Apr 2025Director or officer change8-K
21 Jan 2025Private placement of securities (Form D)$450.0M sold of $450.0M offeredD
13 Jan 2025Signed a major agreementSame filing: sold shares privately8-K
28 Sep 2023Signed a major agreementSame filing: sold shares privately8-K
4 Oct 2022Signed a major agreement8-K
23 Nov 2021Signed a major agreement8-K

12 open postings; careers site tracked since 20 Nov 2026. Most in Marketing & communications 33%, Corporate IT 17%, Supply chain & procurement 17%, Executive & administrative support 8%.

PostedJobLocation
10 Nov 2026Associate Director, Global Clinical Supply ChainSupply chain & procurementRemote
30 Oct 2026Associate Director, BiostatisticsProgram & project managementRemote
29 Oct 2026Senior Manager, Medical CommunicationsMarketing & communicationsRemote
29 Oct 2026Executive Director, MarketingMarketing & communicationsRemote
29 Oct 2026Executive Director, New Product PlanningMarketing & communicationsRemote
28 Oct 2026Director, Infrastructure & Data PlatformsCorporate ITRemote
27 Oct 2026Director, Supply Chain Product PlanningSupply chain & procurementRemote
26 Oct 2026Senior Director, Corporate & Commercial IT Business SystemsCorporate ITRemote
Timeline

Several things at once

Two or more unrelated kinds of records unusual within 30 days

14 Nov 2023confirmed

Confirmed across sources Institutional holdings and Short interest and volume

Immunovant (IMVT): had 7.3M shares sold short in the 29 Sep 2023 report, 2.6× the same report last year, while it saw 56 13F filers open a new position in the quarter ended 30 Sep 2023, 2.7× the same quarter last year. Two unrelated kinds of activity within 28 days.

  • Short interest and volume: Short interest spike, became public on 12 Oct 2023
  • Institutional holdings: Many funds opening a new position, became public on 14 Nov 2023
2022-09-30: 2.9M2022-10-14: 3.0M2022-10-31: 2.7M2022-11-15: 2.9M2022-11-30: 2.6M2022-12-15: 2.8M2022-12-30: 3.6M2023-01-13: 2.4M2023-01-31: 2.3M2023-02-15: 2.9M2023-02-28: 3.4M2023-03-15: 4.0M2023-03-31: 4.9M2023-04-14: 4.7M2023-04-28: 4.5M2023-05-15: 4.3M2023-05-31: 3.4M2023-06-15: 3.4M2023-06-30: 3.7M2023-07-14: 3.6M2023-07-31: 3.7M2023-08-15: 3.8M2023-08-31: 4.9M2023-09-15: 5.1M2023-09-29: 7.3M
The 29 Sep 2023 report against the 24 reports before it. this reportearliernormal: 3.5M
See the evidence (2 changes)

Short interest and volume: Short interest spike became public on 12 Oct 2023

Immunovant had 7.3M shares sold short in the 29 Sep 2023 report, 2.6× the same report last year.

This period
7.3M (the 29 Sep 2023 report)
Normal report (median of 24 earlier)
3.5M
Typical spread (median absolute deviation)
648K
How far from its usual level
+3.9
Same report last year
2.9M
History used
1,368 days
2022-09-30: 2.9M2022-10-14: 3.0M2022-10-31: 2.7M2022-11-15: 2.9M2022-11-30: 2.6M2022-12-15: 2.8M2022-12-30: 3.6M2023-01-13: 2.4M2023-01-31: 2.3M2023-02-15: 2.9M2023-02-28: 3.4M2023-03-15: 4.0M2023-03-31: 4.9M2023-04-14: 4.7M2023-04-28: 4.5M2023-05-15: 4.3M2023-05-31: 3.4M2023-06-15: 3.4M2023-06-30: 3.7M2023-07-14: 3.6M2023-07-31: 3.7M2023-08-15: 3.8M2023-08-31: 4.9M2023-09-15: 5.1M2023-09-29: 7.3M
the 29 Sep 2023 report24 earlier reportsnormal: 3.5M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Institutional holdings: Many funds opening a new position became public on 14 Nov 2023

Immunovant saw 56 13F filers open a new position in the quarter ended 30 Sep 2023, 2.7× the same quarter last year.

This period
56 (the quarter ended 30 Sep 2023)
Normal quarter (median of 8 earlier)
22
Typical spread (median absolute deviation)
5.5
How far from its usual level
+4.2
Same quarter last year
21
History used
1,369 days
2021-09-30: 232021-12-31: 152022-03-31: 82022-06-30: 112022-09-30: 212022-12-31: 372023-03-31: 242023-06-30: 262023-09-30: 56
the quarter ended 30 Sep 20238 earlier quartersnormal: 22

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

Check it at the source: SEC Form 13F data sets.

Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

Timeline

Changes and notable records, by the date each became public

  1. 13 Dec 2025Insiders record

    Roivant Sciences Ltd. (director) bought 16,666,666 shares of IMVT ($350.0M) (dated 12 Dec 2025)

  2. 21 Nov 2025Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  3. 21 Nov 2025Filings record

    Director or officer change

  4. 29 Jul 2025Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  5. 29 Jul 2025Filings record

    Director or officer change

  6. 25 Jul 2025Short interest and volume change

    had 20.6M shares sold short in the 15 Jul 2025 report, 2.0× the same report last year.

    Same report last year: 10.2M; its normal report is 13.1M.

    See the evidence
    This period
    20.6M (the 15 Jul 2025 report)
    Normal report (median of 24 earlier)
    13.1M
    Typical spread (median absolute deviation)
    1.3M
    How far from its usual level
    +4.0
    Same report last year
    10.2M
    History used
    2,023 days
    2024-07-15: 10.2M2024-07-31: 11.2M2024-08-15: 12.2M2024-08-30: 12.4M2024-09-13: 12.5M2024-09-30: 12.6M2024-10-15: 12.9M2024-10-31: 13.1M2024-11-15: 13.0M2024-11-29: 12.7M2024-12-13: 12.6M2024-12-31: 12.3M2025-01-15: 12.8M2025-01-31: 13.1M2025-02-14: 14.8M2025-02-28: 15.4M2025-03-14: 15.8M2025-03-31: 19.7M2025-04-15: 20.8M2025-04-30: 20.7M2025-05-15: 21.4M2025-05-30: 21.7M2025-06-13: 19.9M2025-06-30: 20.4M2025-07-15: 20.6M
    the 15 Jul 2025 report24 earlier reportsnormal: 13.1M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  7. 26 Jun 2025Short interest and volume change

    had 19.9M shares sold short in the 13 Jun 2025 report, 2.0× the same report last year.

    Same report last year: 10.1M; its normal report is 12.9M.

    See the evidence
    This period
    19.9M (the 13 Jun 2025 report)
    Normal report (median of 24 earlier)
    12.9M
    Typical spread (median absolute deviation)
    1.2M
    How far from its usual level
    +4.1
    Same report last year
    10.1M
    History used
    1,991 days
    2024-06-14: 10.1M2024-06-28: 10.0M2024-07-15: 10.2M2024-07-31: 11.2M2024-08-15: 12.2M2024-08-30: 12.4M2024-09-13: 12.5M2024-09-30: 12.6M2024-10-15: 12.9M2024-10-31: 13.1M2024-11-15: 13.0M2024-11-29: 12.7M2024-12-13: 12.6M2024-12-31: 12.3M2025-01-15: 12.8M2025-01-31: 13.1M2025-02-14: 14.8M2025-02-28: 15.4M2025-03-14: 15.8M2025-03-31: 19.7M2025-04-15: 20.8M2025-04-30: 20.7M2025-05-15: 21.4M2025-05-30: 21.7M2025-06-13: 19.9M
    the 13 Jun 2025 report24 earlier reportsnormal: 12.9M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  8. 11 Jun 2025Short interest and volume change

    had 21.7M shares sold short in the 30 May 2025 report, 2.4× the same report last year.

    Same report last year: 9.2M; its normal report is 12.7M.

    See the evidence
    This period
    21.7M (the 30 May 2025 report)
    Normal report (median of 24 earlier)
    12.7M
    Typical spread (median absolute deviation)
    1.0M
    How far from its usual level
    +5.9
    Same report last year
    9.2M
    History used
    1,977 days
    2024-05-31: 9.2M2024-06-14: 10.1M2024-06-28: 10.0M2024-07-15: 10.2M2024-07-31: 11.2M2024-08-15: 12.2M2024-08-30: 12.4M2024-09-13: 12.5M2024-09-30: 12.6M2024-10-15: 12.9M2024-10-31: 13.1M2024-11-15: 13.0M2024-11-29: 12.7M2024-12-13: 12.6M2024-12-31: 12.3M2025-01-15: 12.8M2025-01-31: 13.1M2025-02-14: 14.8M2025-02-28: 15.4M2025-03-14: 15.8M2025-03-31: 19.7M2025-04-15: 20.8M2025-04-30: 20.7M2025-05-15: 21.4M2025-05-30: 21.7M
    the 30 May 2025 report24 earlier reportsnormal: 12.7M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  9. 28 May 2025Short interest and volume change

    had 21.4M shares sold short in the 15 May 2025 report, 2.3× the same report last year.

    Same report last year: 9.3M; its normal report is 12.7M.

    See the evidence
    This period
    21.4M (the 15 May 2025 report)
    Normal report (median of 24 earlier)
    12.7M
    Typical spread (median absolute deviation)
    971K
    How far from its usual level
    +6.1
    Same report last year
    9.3M
    History used
    1,962 days
    2024-05-15: 9.3M2024-05-31: 9.2M2024-06-14: 10.1M2024-06-28: 10.0M2024-07-15: 10.2M2024-07-31: 11.2M2024-08-15: 12.2M2024-08-30: 12.4M2024-09-13: 12.5M2024-09-30: 12.6M2024-10-15: 12.9M2024-10-31: 13.1M2024-11-15: 13.0M2024-11-29: 12.7M2024-12-13: 12.6M2024-12-31: 12.3M2025-01-15: 12.8M2025-01-31: 13.1M2025-02-14: 14.8M2025-02-28: 15.4M2025-03-14: 15.8M2025-03-31: 19.7M2025-04-15: 20.8M2025-04-30: 20.7M2025-05-15: 21.4M
    the 15 May 2025 report24 earlier reportsnormal: 12.7M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  10. 10 May 2025Short interest and volume change

    had 20.7M shares sold short in the 30 Apr 2025 report, 2.3× the same report last year.

    Same report last year: 9.0M; its normal report is 12.6M.

    See the evidence
    This period
    20.7M (the 30 Apr 2025 report)
    Normal report (median of 24 earlier)
    12.6M
    Typical spread (median absolute deviation)
    971K
    How far from its usual level
    +5.6
    Same report last year
    9.0M
    History used
    1,947 days
    2024-04-30: 9.0M2024-05-15: 9.3M2024-05-31: 9.2M2024-06-14: 10.1M2024-06-28: 10.0M2024-07-15: 10.2M2024-07-31: 11.2M2024-08-15: 12.2M2024-08-30: 12.4M2024-09-13: 12.5M2024-09-30: 12.6M2024-10-15: 12.9M2024-10-31: 13.1M2024-11-15: 13.0M2024-11-29: 12.7M2024-12-13: 12.6M2024-12-31: 12.3M2025-01-15: 12.8M2025-01-31: 13.1M2025-02-14: 14.8M2025-02-28: 15.4M2025-03-14: 15.8M2025-03-31: 19.7M2025-04-15: 20.8M2025-04-30: 20.7M
    the 30 Apr 2025 report24 earlier reportsnormal: 12.6M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  11. 26 Apr 2025Short interest and volume change

    had 20.8M shares sold short in the 15 Apr 2025 report, 2.4× the same report last year.

    Same report last year: 8.5M; its normal report is 12.5M.

    See the evidence
    This period
    20.8M (the 15 Apr 2025 report)
    Normal report (median of 24 earlier)
    12.5M
    Typical spread (median absolute deviation)
    971K
    How far from its usual level
    +5.8
    Same report last year
    8.5M
    History used
    1,932 days
    2024-04-15: 8.5M2024-04-30: 9.0M2024-05-15: 9.3M2024-05-31: 9.2M2024-06-14: 10.1M2024-06-28: 10.0M2024-07-15: 10.2M2024-07-31: 11.2M2024-08-15: 12.2M2024-08-30: 12.4M2024-09-13: 12.5M2024-09-30: 12.6M2024-10-15: 12.9M2024-10-31: 13.1M2024-11-15: 13.0M2024-11-29: 12.7M2024-12-13: 12.6M2024-12-31: 12.3M2025-01-15: 12.8M2025-01-31: 13.1M2025-02-14: 14.8M2025-02-28: 15.4M2025-03-14: 15.8M2025-03-31: 19.7M2025-04-15: 20.8M
    the 15 Apr 2025 report24 earlier reportsnormal: 12.5M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  12. 21 Apr 2025Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  13. 21 Apr 2025Filings record

    Director or officer change

  14. 10 Apr 2025Short interest and volume change

    had 19.7M shares sold short in the 31 Mar 2025 report, 2.2× the same report last year.

    Same report last year: 9.0M; its normal report is 12.4M.

    See the evidence
    This period
    19.7M (the 31 Mar 2025 report)
    Normal report (median of 24 earlier)
    12.4M
    Typical spread (median absolute deviation)
    971K
    How far from its usual level
    +5.0
    Same report last year
    9.0M
    History used
    1,917 days
    2024-03-28: 9.0M2024-04-15: 8.5M2024-04-30: 9.0M2024-05-15: 9.3M2024-05-31: 9.2M2024-06-14: 10.1M2024-06-28: 10.0M2024-07-15: 10.2M2024-07-31: 11.2M2024-08-15: 12.2M2024-08-30: 12.4M2024-09-13: 12.5M2024-09-30: 12.6M2024-10-15: 12.9M2024-10-31: 13.1M2024-11-15: 13.0M2024-11-29: 12.7M2024-12-13: 12.6M2024-12-31: 12.3M2025-01-15: 12.8M2025-01-31: 13.1M2025-02-14: 14.8M2025-02-28: 15.4M2025-03-14: 15.8M2025-03-31: 19.7M
    the 31 Mar 2025 report24 earlier reportsnormal: 12.4M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  15. 21 Jan 2025Filings record

    Private placement of securities (Form D)

  16. 16 Jan 2025Insiders record

    Roivant Sciences Ltd. (director) bought 16,845,010 shares of IMVT ($336.9M) (dated 15 Jan 2025)

  17. 14 Nov 2023several at once

    had 7.3M shares sold short in the 29 Sep 2023 report, 2.6× the same report last year, while it saw 56 13F filers open a new position in the quarter ended 30 Sep 2023, 2.7× the same quarter last year. Two unrelated kinds of activity within 28 days.

    See the evidence (2 changes)

    Short interest and volume: Short interest spike became public on 12 Oct 2023

    Immunovant had 7.3M shares sold short in the 29 Sep 2023 report, 2.6× the same report last year.

    This period
    7.3M (the 29 Sep 2023 report)
    Normal report (median of 24 earlier)
    3.5M
    Typical spread (median absolute deviation)
    648K
    How far from its usual level
    +3.9
    Same report last year
    2.9M
    History used
    1,368 days
    2022-09-30: 2.9M2022-10-14: 3.0M2022-10-31: 2.7M2022-11-15: 2.9M2022-11-30: 2.6M2022-12-15: 2.8M2022-12-30: 3.6M2023-01-13: 2.4M2023-01-31: 2.3M2023-02-15: 2.9M2023-02-28: 3.4M2023-03-15: 4.0M2023-03-31: 4.9M2023-04-14: 4.7M2023-04-28: 4.5M2023-05-15: 4.3M2023-05-31: 3.4M2023-06-15: 3.4M2023-06-30: 3.7M2023-07-14: 3.6M2023-07-31: 3.7M2023-08-15: 3.8M2023-08-31: 4.9M2023-09-15: 5.1M2023-09-29: 7.3M
    the 29 Sep 2023 report24 earlier reportsnormal: 3.5M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Institutional holdings: Many funds opening a new position became public on 14 Nov 2023

    Immunovant saw 56 13F filers open a new position in the quarter ended 30 Sep 2023, 2.7× the same quarter last year.

    This period
    56 (the quarter ended 30 Sep 2023)
    Normal quarter (median of 8 earlier)
    22
    Typical spread (median absolute deviation)
    5.5
    How far from its usual level
    +4.2
    Same quarter last year
    21
    History used
    1,369 days
    2021-09-30: 232021-12-31: 152022-03-31: 82022-06-30: 112022-09-30: 212022-12-31: 372023-03-31: 242023-06-30: 262023-09-30: 56
    the quarter ended 30 Sep 20238 earlier quartersnormal: 22

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

    Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

  18. 14 Nov 2023Institutional holdings change

    saw 56 13F filers open a new position in the quarter ended 30 Sep 2023, 2.7× the same quarter last year.

    Same quarter last year: 21; its normal quarter is 22.

    See the evidence
    This period
    56 (the quarter ended 30 Sep 2023)
    Normal quarter (median of 8 earlier)
    22
    Typical spread (median absolute deviation)
    5.5
    How far from its usual level
    +4.2
    Same quarter last year
    21
    History used
    1,369 days
    2021-09-30: 232021-12-31: 152022-03-31: 82022-06-30: 112022-09-30: 212022-12-31: 372023-03-31: 242023-06-30: 262023-09-30: 56
    the quarter ended 30 Sep 20238 earlier quartersnormal: 22

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

  19. 12 Oct 2023Short interest and volume change

    had 7.3M shares sold short in the 29 Sep 2023 report, 2.6× the same report last year.

    Same report last year: 2.9M; its normal report is 3.5M.

    See the evidence
    This period
    7.3M (the 29 Sep 2023 report)
    Normal report (median of 24 earlier)
    3.5M
    Typical spread (median absolute deviation)
    648K
    How far from its usual level
    +3.9
    Same report last year
    2.9M
    History used
    1,368 days
    2022-09-30: 2.9M2022-10-14: 3.0M2022-10-31: 2.7M2022-11-15: 2.9M2022-11-30: 2.6M2022-12-15: 2.8M2022-12-30: 3.6M2023-01-13: 2.4M2023-01-31: 2.3M2023-02-15: 2.9M2023-02-28: 3.4M2023-03-15: 4.0M2023-03-31: 4.9M2023-04-14: 4.7M2023-04-28: 4.5M2023-05-15: 4.3M2023-05-31: 3.4M2023-06-15: 3.4M2023-06-30: 3.7M2023-07-14: 3.6M2023-07-31: 3.7M2023-08-15: 3.8M2023-08-31: 4.9M2023-09-15: 5.1M2023-09-29: 7.3M
    the 29 Sep 2023 report24 earlier reportsnormal: 3.5M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  20. 5 Oct 2023Insiders record

    Roivant Sciences Ltd. (director) bought 1,526,316 shares of IMVT ($58.0M) (dated 4 Oct 2023)

  21. 26 Apr 2023Short interest and volume change

    had 4.7M shares sold short in the 14 Apr 2023 report, 1.9× the same report last year.

    Same report last year: 2.4M; its normal report is 2.6M.

    See the evidence
    This period
    4.7M (the 14 Apr 2023 report)
    Normal report (median of 24 earlier)
    2.6M
    Typical spread (median absolute deviation)
    318K
    How far from its usual level
    +4.5
    Same report last year
    2.4M
    History used
    1,200 days
    2022-04-14: 2.4M2022-04-29: 2.5M2022-05-13: 2.3M2022-05-31: 2.3M2022-06-15: 2.1M2022-06-30: 1.8M2022-07-15: 1.8M2022-07-29: 1.6M2022-08-15: 1.6M2022-08-31: 1.7M2022-09-15: 2.7M2022-09-30: 2.9M2022-10-14: 3.0M2022-10-31: 2.7M2022-11-15: 2.9M2022-11-30: 2.6M2022-12-15: 2.8M2022-12-30: 3.6M2023-01-13: 2.4M2023-01-31: 2.3M2023-02-15: 2.9M2023-02-28: 3.4M2023-03-15: 4.0M2023-03-31: 4.9M2023-04-14: 4.7M
    the 14 Apr 2023 report24 earlier reportsnormal: 2.6M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  22. 13 Apr 2023Short interest and volume change

    had 4.9M shares sold short in the 31 Mar 2023 report, 2.1× the same report last year.

    Same report last year: 2.3M; its normal report is 2.5M.

    See the evidence
    This period
    4.9M (the 31 Mar 2023 report)
    Normal report (median of 24 earlier)
    2.5M
    Typical spread (median absolute deviation)
    388K
    How far from its usual level
    +4.2
    Same report last year
    2.3M
    History used
    1,186 days
    2022-03-31: 2.3M2022-04-14: 2.4M2022-04-29: 2.5M2022-05-13: 2.3M2022-05-31: 2.3M2022-06-15: 2.1M2022-06-30: 1.8M2022-07-15: 1.8M2022-07-29: 1.6M2022-08-15: 1.6M2022-08-31: 1.7M2022-09-15: 2.7M2022-09-30: 2.9M2022-10-14: 3.0M2022-10-31: 2.7M2022-11-15: 2.9M2022-11-30: 2.6M2022-12-15: 2.8M2022-12-30: 3.6M2023-01-13: 2.4M2023-01-31: 2.3M2023-02-15: 2.9M2023-02-28: 3.4M2023-03-15: 4.0M2023-03-31: 4.9M
    the 31 Mar 2023 report24 earlier reportsnormal: 2.5M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  23. 8 Oct 2022Insiders change

    had 3 insiders buy $2.7M of its shares on the open market within 30 days (3 filings).

    Who bought: Torti Frank, Pande Atul, Roivant Sciences Ltd..

    See the evidence (3 source records)
    Independent buyers
    3
    Purchase filings (Form 4, code P)
    3
    Total bought
    $2.7M
    Window
    8 Sep 2022 to 8 Oct 2022

    Fires when at least 3 independent insiders (joint filers count once) buy on the open market in 30 days, in at least 2 filings, for $100K or more in total; amendments do not count.

  24. 8 Oct 2022Insiders record

    Roivant Sciences Ltd. (ten percent owner) bought 416,667 shares of IMVT ($2.5M) (dated 7 Oct 2022)

  25. 5 Oct 2022Insiders record

    Pande Atul (director) bought 15,000 shares of IMVT ($84,000) (dated 4 Oct 2022)

  26. 30 Sep 2022Insiders record

    Torti Frank (director) bought 20,000 shares of IMVT ($116,200) (dated 29 Sep 2022)

  27. 15 Sep 2021Filings record

    Director or officer change

  28. 31 Aug 2021Insiders record

    Hughes Douglas J. (director) bought 18,247 shares of IMVT ($150,355) (dated 30 Aug 2021)

  29. 21 Aug 2021Insiders change

    had 3 insiders buy $137K of its shares on the open market within 30 days (3 filings).

    Who bought: Fromkin Andrew J., Pande Atul, Migausky George V.

    See the evidence (3 source records)
    Independent buyers
    3
    Purchase filings (Form 4, code P)
    3
    Total bought
    $137K
    Window
    22 Jul 2021 to 21 Aug 2021

    Fires when at least 3 independent insiders (joint filers count once) buy on the open market in 30 days, in at least 2 filings, for $100K or more in total; amendments do not count.

  30. 21 Aug 2021Insiders record

    MIGAUSKY GEORGE V (director) bought 7,000 shares of IMVT ($53,550) (dated 20 Aug 2021)

  31. 17 Aug 2021Insiders record

    Pande Atul (director) bought 5,000 shares of IMVT ($39,900) (dated 16 Aug 2021)

  32. 12 Aug 2021Insiders record

    Fromkin Andrew J. (director) bought 5,500 shares of IMVT ($43,450) (dated 11 Aug 2021)

  33. 2 Aug 2021Filings record

    Director or officer change

  34. 13 Jul 2021Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  35. 13 Jul 2021Filings record

    Director or officer change

  36. 12 May 2021Short interest and volume change

    had 5.7M shares sold short in the 30 Apr 2021 report, 3.7× the same report last year.

    Same report last year: 1.5M; its normal report is 1.7M.

    See the evidence
    This period
    5.7M (the 30 Apr 2021 report)
    Normal report (median of 24 earlier)
    1.7M
    Typical spread (median absolute deviation)
    684K
    How far from its usual level
    +4.0
    Same report last year
    1.5M
    History used
    486 days
    2020-04-30: 1.5M2020-05-15: 1.4M2020-05-29: 1.0M2020-06-15: 438K2020-06-30: 1.3M2020-07-15: 1.2M2020-07-31: 1.1M2020-08-14: 930K2020-08-31: 1.2M2020-09-15: 1.5M2020-09-30: 2.4M2020-10-15: 2.5M2020-10-30: 2.4M2020-11-13: 1.9M2020-11-30: 1.4M2020-12-15: 1.3M2020-12-31: 2.7M2021-01-15: 2.5M2021-01-29: 2.5M2021-02-12: 3.4M2021-02-26: 3.8M2021-03-15: 4.6M2021-03-31: 6.5M2021-04-15: 5.8M2021-04-30: 5.7M
    the 30 Apr 2021 report24 earlier reportsnormal: 1.7M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  37. 27 Apr 2021Short interest and volume change

    had 5.8M shares sold short in the 15 Apr 2021 report, 4.9× the same report last year.

    Same report last year: 1.2M; its normal report is 1.5M.

    See the evidence
    This period
    5.8M (the 15 Apr 2021 report)
    Normal report (median of 24 earlier)
    1.5M
    Typical spread (median absolute deviation)
    566K
    How far from its usual level
    +5.0
    Same report last year
    1.2M
    History used
    471 days
    2020-04-15: 1.2M2020-04-30: 1.5M2020-05-15: 1.4M2020-05-29: 1.0M2020-06-15: 438K2020-06-30: 1.3M2020-07-15: 1.2M2020-07-31: 1.1M2020-08-14: 930K2020-08-31: 1.2M2020-09-15: 1.5M2020-09-30: 2.4M2020-10-15: 2.5M2020-10-30: 2.4M2020-11-13: 1.9M2020-11-30: 1.4M2020-12-15: 1.3M2020-12-31: 2.7M2021-01-15: 2.5M2021-01-29: 2.5M2021-02-12: 3.4M2021-02-26: 3.8M2021-03-15: 4.6M2021-03-31: 6.5M2021-04-15: 5.8M
    the 15 Apr 2021 report24 earlier reportsnormal: 1.5M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  38. 13 Apr 2021Short interest and volume change

    had 6.5M shares sold short in the 31 Mar 2021 report, 9.6× the same report last year.

    Same report last year: 672K; its normal report is 1.5M.

    See the evidence
    This period
    6.5M (the 31 Mar 2021 report)
    Normal report (median of 24 earlier)
    1.5M
    Typical spread (median absolute deviation)
    497K
    How far from its usual level
    +6.8
    Same report last year
    672K
    History used
    456 days
    2020-03-31: 672K2020-04-15: 1.2M2020-04-30: 1.5M2020-05-15: 1.4M2020-05-29: 1.0M2020-06-15: 438K2020-06-30: 1.3M2020-07-15: 1.2M2020-07-31: 1.1M2020-08-14: 930K2020-08-31: 1.2M2020-09-15: 1.5M2020-09-30: 2.4M2020-10-15: 2.5M2020-10-30: 2.4M2020-11-13: 1.9M2020-11-30: 1.4M2020-12-15: 1.3M2020-12-31: 2.7M2021-01-15: 2.5M2021-01-29: 2.5M2021-02-12: 3.4M2021-02-26: 3.8M2021-03-15: 4.6M2021-03-31: 6.5M
    the 31 Mar 2021 report24 earlier reportsnormal: 1.5M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  39. 25 Mar 2021Short interest and volume change

    had 4.6M shares sold short in the 15 Mar 2021 report, 5.6× the same report last year.

    Same report last year: 814K; its normal report is 1.4M.

    See the evidence
    This period
    4.6M (the 15 Mar 2021 report)
    Normal report (median of 24 earlier)
    1.4M
    Typical spread (median absolute deviation)
    497K
    How far from its usual level
    +4.3
    Same report last year
    814K
    History used
    440 days
    2020-03-13: 814K2020-03-31: 672K2020-04-15: 1.2M2020-04-30: 1.5M2020-05-15: 1.4M2020-05-29: 1.0M2020-06-15: 438K2020-06-30: 1.3M2020-07-15: 1.2M2020-07-31: 1.1M2020-08-14: 930K2020-08-31: 1.2M2020-09-15: 1.5M2020-09-30: 2.4M2020-10-15: 2.5M2020-10-30: 2.4M2020-11-13: 1.9M2020-11-30: 1.4M2020-12-15: 1.3M2020-12-31: 2.7M2021-01-15: 2.5M2021-01-29: 2.5M2021-02-12: 3.4M2021-02-26: 3.8M2021-03-15: 4.6M
    the 15 Mar 2021 report24 earlier reportsnormal: 1.4M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  40. 16 Sep 2020Insiders record

    Butchko Julia G. (Chief Dev. & Tech. Officer) bought 5,000 shares of IMVT ($190,850) (dated 15 Sep 2020)

Showing the newest 40 of 70 entries; narrow the window or the kind of data to see older ones.

Not listed: 278 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.

Identifiers and sources

How records are matched to this company, and what each source holds for it

Cik
0001764013
Ticker
IMVT
Domain
immunovant.com
Hq location
NC|DURHAM|27713 (1 unverified)
Name
Health Sciences Acquisitions Corp, Immunovant, Inc.
Wikidata
Q140045442
  • SEC Form 13F institutional holdings252 data points31 Dec 2019 to 30 Sep 2026
  • SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)112 records15 Apr 2019 to 9 Nov 2026
  • SEC XBRL company facts (revenue, capex, R&D, backlog...)386 data points31 Mar 2018 to 3 Nov 2026
  • SEC Form 4 insider transactions212 records, 452 data points12 Nov 2019 to 12 Nov 2026
  • FINRA short interest (twice monthly)492 data points31 Dec 2019 to 30 Oct 2026
  • FINRA daily short sale volume (off-exchange)3480 data points19 Dec 2019 to 20 Nov 2026